REFERENCES
- Geffen, D.B., Fisher, RI., Longo, D.L., Young, R.C. and De Vita Jr. V.T. (1985) "Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy", Journal of Clinical Oncology, 3, 646 — 653.
- Boye, J., Elter, T. and Engert, A. (2003) "An overview of the current use of the anti-CD20 monoclonal antibody rituximab", Annals of Oncology, 14, 520 — 535.
- Coiffer, B., Lepage, E., Briere J., et al. (2003) "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-b-cell lymphoma", New England Journal of Medicine, 346, 235–242.
- Cerny, T., Borish, B., Introna M., et al. (2002) "Mechanism of action of rituximab", Anticancer Drugs, Suppl 2, 3–10.
- Mangel, J., Buckshtein, R., Imrie, K., et al. (2003) "Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation", Annals of Oncol-ogy, 14, 758–756.
- Ostronoff, M., Matias, C., Matias, K., et al. (2002) "Fractionated mabthera (rituximab) in anuric acute renal failure patients." (2002) Proceedings of American Society of Hematology. Abstract #4768.
- Elena A.P., Dainer, P.M. and Kallab, AM. (2002) "Treatment of patient with end stage renal disease with rituximab: pharmacoki-netic evaluation suggests rituximab is not eliminated by hemodia-lisis", American Journal of Hematology, 71, 219 — 222.
- Castro, M., Van Auken, J., Sponzo, R., et al. (2001) "Successful use of anti-CD20 monoclonal antibody, rituximab, in patients with non-Hodgkin's lymphoma and renal insufficiency", Proceedings of the American Society of Clinical Oncology Abstract #2682.